Isradipine plasma pharmacokinetics and exposure-response in early Parkinson's disease.

ABSTRACT:

Objectives

Isradipine is a dihydropyridine calcium channel inhibitor that has demonstrated concentration-dependent neuroprotective effects in animal models of Parkinson's disease (PD) but failed to show efficacy in a phase 3 clinical trial. The objectives of this study were to model the plasma pharmacokinetics of isradipine in study participants from the phase 3 trial; and, to investigate associations between drug exposure and longitudinal clinical outcome measures of PD progression.

Methods

Plasma samples from nearly all study participants randomized to immediate-release isradipine 5-mg twice daily (166 of 170) were collected for population pharmacokinetic modeling. Estimates of isradipine exposure included apparent oral clearance and area under the concentration-time curve

SUBMITTER: Venuto CS 

PROVIDER: S-EPMC7951102 | biostudies-literature | 2021 Mar

REPOSITORIES: biostudies-literature